A potential clinical question linked to SGLT2 inhibitor therapy as adjunctive-to-insulin in T1DM is the degree of possible insulin dose adjustment that may be required upon initiation of treatment to minimize a potential hypoglycemia risk. The gene discussed is INS; the disease is type 1 diabetes mellitus.